Phase 2a clinical trial has started for NLX-112 (befiradol) funded by Parkinson’s UK and The Michael J. Fox Foundation (MJFF)
Prof. Per Svenningsson, MD, PhD, Principal Clinical Investigator of the study said:
“We are excited to be testing NLX-112 as a novel treatment for LID. If the striking profile of NLX-112 seen in preclinical models translates to the clinical setting, it could significantly improve the quality of life of many Parkinson’s disease patients for whom dyskinesia prevents them from performing routine daily tasks.”